TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06964230: A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Sponsor: T3D Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 376 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT06964230 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06964230 Rescue Dossier →